GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » INIFY Laboratories AB (OSL:INIFY) » Definitions » Debt-to-Asset

INIFY Laboratories AB (OSL:INIFY) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is INIFY Laboratories AB Debt-to-Asset?

INIFY Laboratories AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. INIFY Laboratories AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. INIFY Laboratories AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was kr43.82 Mil. INIFY Laboratories AB's debt to asset for the quarter that ended in Dec. 2024 was 0.00.


INIFY Laboratories AB Debt-to-Asset Historical Data

The historical data trend for INIFY Laboratories AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INIFY Laboratories AB Debt-to-Asset Chart

INIFY Laboratories AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
- - - -

INIFY Laboratories AB Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of INIFY Laboratories AB's Debt-to-Asset

For the Diagnostics & Research subindustry, INIFY Laboratories AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INIFY Laboratories AB's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, INIFY Laboratories AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where INIFY Laboratories AB's Debt-to-Asset falls into.


;
;

INIFY Laboratories AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

INIFY Laboratories AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

INIFY Laboratories AB's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


INIFY Laboratories AB  (OSL:INIFY) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


INIFY Laboratories AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of INIFY Laboratories AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


INIFY Laboratories AB Business Description

Traded in Other Exchanges
N/A
Address
Scheeles vag 3, Solna, SWE, 171 65
INIFY Laboratories AB provides cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized, and AI-supported workflow to optimize quality and response times, initially within the prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer's organization.

INIFY Laboratories AB Headlines

No Headlines